Viriom Inc., of San Diego, reported top-line results from its phase IIb comparator study of Elpida vs. Sustiva (efavirenz, Bristol-Myers Squibb Co.) in combination with tenofovir/emtricitabine (TDF/FTC, Gilead Sciences Inc.) at the Conference on Retroviruses and Opportunistic Infections in Seattle.